

NSH 1226


**NORTHSIDE HOSPITAL
CANCER INSTITUTE**



**NORTHSIDE HOSPITAL
CANCER INSTITUTE**
IMMUNOTHERAPY PROGRAM

**The Blood & Marrow
Transplant Group**
O F G E O R G I A

northside.com/immunotherapy | bmtga.com

PHASE I/II **Clinical Trial Opening**

For Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients

Northside Cancer Institute Immunotherapy Program is opening a Phase I/II study. Phase I will include a dose-finding part to determine the Recommended Dose (RD) of JCAR017 monotherapy in subjects with R/R CLL or SLL, followed by a Phase II expansion to further evaluate the efficacy and safety of JCAR017 monotherapy administered at the RD. A separate Phase 1 cohort will assess the combination of JCAR017 and concurrent ibrutinib. Safety, efficacy, PK and toxicity of JCAR017 will be evaluated.

 **BUILT TO BEAT CANCER**

PRIMARY OBJECTIVE

- **Phase 1 Monotherapy** - To evaluate the safety & to determine the RD of JCAR017 in subjects with R/R CLL or SLL.
- **Phase 1 Combination** - To evaluate the safety & to determine the RD of ibrutinib +JCAR017 in subjects with R/R CLL or SLL.
- **Phase 2 Expansion** - To evaluate anti-tumor activity of JCAR017 at the RD in subjects with R/R CLL or SLL.

CRITERIA

Select Inclusion Criteria

- Age \geq 18
- CLL w/clinically measureable disease
- SLL w/measurable disease
- Has received and failed Bruton tyrosine kinase inhibitor (BTKi) treatment or is ineligible for BTKi treatment

Select Exclusion Criteria

- Known active CNS involvement
- History of another primary malignancy < 2 years
- Richter's transformation

If you have any questions, would like to discuss study logistics, or the eligibility of any patients, please contact Stacey Brown, NH BMT/Leukemia Clinical Research Manager, at **404-780-7965** or stacey.brown@northside.com.



NORTHSIDE HOSPITAL

CANCER INSTITUTE

5670 Peachtree Dunwoody Road
Suite 1000
Atlanta, GA 30342

Presorted
First-Class Mail
U.S. Postage PAID
Atlanta, GA
Permit #1713